Source: Annual Congress 2011 - Tuberculosis in immunocompromised hosts
Disease area: Respiratory infections

Abstract

Aim:It is a known fact that risk of tubercolosis infection is increased with tumor necrosis factor-alfa (TNF-α) blocker treatment. In this study we evaluated the last 6 years follow up data of the patients who admitted to our clinic for tuberculosis scanning before and during TNF-α blocker treatment.
Method: Total of 2335 patients‘ follow up datas were evaluated between February 2005 and February 2011.Statistical analysis were done by using SPSS 15.0 statistical program.
Results: There were 1186 (51%) male, 1149 (49%) female of total number of 2335 patients. Mean age was 40.32±14.67 years. Patients with the diagnosis of rheumatoid arthritis 785 (33.6%), ankylosing spondylitis 912 (39.1%), psoriatic arthritis 193 (8.3%), Behçet disease 85 (3.6%), Chron disease 65 (2.8%), juvenil rheumatoid artritis 142 (6.1%). 781 (33.9%) of the subjects had smoking history of an average 15.07±13.57 pack-year. 792 (33.9%) patients treated with Etanercept, 725 (31.0%) Infliximab, 567 (24.3%) Adalimumab. 66 (2.8%) patients had treatment for tuberculosis in the past, 112 (4.8%) patients had diabetes mellitus. Acording to RAED II (The Society for Research and Education in Rheumatology) Guideline; PPD was ≥5 mm in 1340 (57%), 101 (4.3%)had radiological fibrous lesion, 12 (0.5%) had contact history with tuberculosis. 1308 (56.0%) patients were given preventive treatment with Izoniazid. In these 6 years fallow up, 4(171/100.000) patients had tuberculosis infection; 2 were miliary tuberculosis (one of them was multidrug resistant), 1 was gastrointestinal tuberculosis and the last one was relaps patient with a history of tuberculosis.
Conclusion: This results supported that close follow up of patients who used TNF-α blocker was so important.

Rating:

Share or cite this content

Citations should be made in the following way:
S. Börekçi, B. Duman, N. Mazican, K. Tascilar, B. Müsellim, G. Öngen, V. Hamuryudan (Istanbul, Turkey). Tumor nekrozis faktor-alfa blockers and tuberculosis – Analysis of the 6 years. Eur Respir J 2011; 38: Suppl. 55, 1946

Member's Comments

No comment yet.

Related content which might interest you: Asthma control test – Suitable for children from 4 to 11 years? Source: Annual Congress 2010 - Quality of life, asthma control and monitoring childhood asthma Year: 2010 Tracheobronchopathia osteochondroplastica – Analysis of 10 years period Source: Annual Congress 2012 - Respiratory manifestations of systemic disease: a holistic approach Year: 2012 Tuberculosis – is there anything different over a decade? Source: Annual Congress 2009 - Socio-economic impact of tuberculosis Year: 2009 Interferon gamma release assays in screening for tuberculosis – Can we use them in patients with sarcoidosis? Source: Annual Congress 2011 - Different profiles of sarcoidosis and other granulomatous disorders Year: 2011 Kidney tuberculosis in last century and now – Is it the same disease? Source: Annual Congress 2011 - Pulmonary and extrapulmonary tuberculosis Year: 2011 Treatment of sarcoidosis – pentoxifylline Source: Annual Congress 2009 - Pleural and parenchymal diseases Year: 2009 Bacterial multidrug-resistance profile in a respiratory insufficiency unit – Analysis of 17 months Source: Annual Congress 2012 - Management of pneumonia due to hospital pathogens Year: 2012 Miliary tuberculosis during treatment with anti TNF alpha – A report of three cases Source: Annual Congress 2012 - Tuberculosis: clinical findings I Year: 2012 Post-menopausal mammary tuberculosis – Report of three cases Source: Annual Congress 2011 - Management of tuberculosis Year: 2011 Paraganglioma of the mediastinum – 18 years experience Source: Annual Congress 2009 - Diagnosis of pleural effusions and rare tumours experience Year: 2009 Regional reference centre for multi-drug resistant tuberculosis – 11 months of activity Source: Annual Congress 2010 - Emerging drug resistance in tuberculosis Year: 2010 The in-vitro pharmacology of PF-4522971 – A novel inhaled Muscarinic M3 Antagonist Source: Annual Congress 2010 - Regulation of airway hyperresponsiveness and bronchodilators Year: 2010 The results of drug resistance survey of MDR-strains on second line drugs obtains in national reference laboratory – " M.Nasta " Institute – Bucharest Source: Annual Congress 2011 - Epidemiology of multidrug-resistant and extensively drug-resistant tuberculosis Year: 2011 T spot TB reactivity – ²to treat or not to treat² Source: Annual Congress 2009 - Clinical immunology of tuberculosis Year: 2009 Surgical treatment of pulmonary sequestration – 15-years experience Source: Annual Congress 2010 - Congenital lesions and rare pathology Year: 2010 Pulmonary tuberculosis – Still a challenging diagnosis Source: Annual Congress 2011 - Clinical tuberculosis Year: 2011 Lung function in young adults – Which references should be taken? Source: Annual Congress 2010 - Methods in respiratory epidemiology Year: 2010 Clinical evaluation in 14 cases of diffuse alveolar hemorrhage – Relationship between initial findings and prognosis – Source: Annual Congress 2010 - Rare diffuse lung diseases Year: 2010 Cryptogenic organising pneumonia – clarithromycin treatment – factors influencing treatment results and relapses Source: Annual Congress 2009 - Various backgrounds in diffuse parenchymal lung disease Year: 2009 Outcome of zinc & vit-A supplementation in the treatment multidrug resistance pulmonary tuberculosis patients Source: Annual Congress 2010 - Tuberculosis drug resistance Year: 2010